Eligibility AZD1152 and LDAC in AML
ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Eligibility AZD1152 and LDAC in AML

  1. StudyEvent: Eligibility
    1. Eligibility AZD1152 and LDAC in AML
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)